DEVELOPER: Moderna
TECHNOLOGY: mRNA
EFFICACY: 94,1%
CLINICAL TRIALS: P3 completed.
DOSE: 2 doses, 28 days apart
STORAGE: 30 days with refrigeration, 6 months at -20 C
DEVELOPER: Pfizer-BioNTech
TECHNOLOGY: mRNA
EFFICACY: 95%
CLINICAL TRIALS: P3 completed.
DOSE: 2 doses, 21 days apart
STORAGE: Freezer storage at -70C, 5 days with refrigeration
DEVELOPER: Oxford-AstraZeneca
TECHNOLOGY: Viral Vector
EFFICACY: 62% at the approved dosing scheme
CLINICAL TRIALS: P3 completed.
DOSE: 2 doses, 4 weeks apart
STORAGE: refrigerated at 2-8C
DEVELOPER: Johnson & Johnson
TECHNOLOGY: Viral Vector
EFFICACY: ???
CLINICAL TRIALS: P3 completed.
DOSE: 1 and 2 doses schemes are being tested
STORAGE: 2 years frozen at - 20C. 3 months refrigerated at 2-8C
DEVELOPER: Gamaleya
TECHNOLOGY: Viral Vector
EFFICACY: 91.4% ?????
CLINICAL TRIALS: P3 completed.
DOSE: 2 doses, 3 weeks apart
STORAGE: Freezer storage ( 20)C
DEVELOPER: Sinopharm
TECHNOLOGY: Inactivated Virus
EFFICACY: 79.34 (86% in UAE trial) Unpublished data
CLINICAL TRIALS: P3 trials are ongoing.
DOSE: 2 doses, 3 weeks apart
STORAGE: refrigerated at 2-8C
